ScripXiamen Amoytop Biotech, a Chinese biopharma focused on liver diseases and oncology, has stood out among its peers by becoming the first in years to acquire a pre-revenue compatriot biotech company. Sh
ScripLess than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy candidate giroctocogene fitelparvovec, the big pharma has decided t
ScripBioMarin Pharmaceuticals foresees its achondroplasia drug Voxzogo (vosoritide) having a strong competitive position in the years to come given the drug’s established position and the “stickiness” of t
ScripBioMarin chief business officer James Sabry is known as one of the industry’s most prolific dealmakers, having joined the rare disease specialist last year from Roche, where he led pharma partnering.